Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity

Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date. The post Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity appeared first on…

Read More

Why Hospitals Are Losing the Financial Tug-of-War With Payers

Hospitals’ flat revenues are clashing with rising costs and excessive reimbursement denials from payers, said Rod Hanners, CEO of Keck Medicine of USC. He warned that policy efforts focused solely on limiting provider payments ignore the larger issue of unchecked profits among payers, drugmakers and other healthcare industry players. The post Why Hospitals Are Losing…

Read More